Your browser doesn't support javascript.
loading
Associations between COVID-19 therapies and inpatient gastrointestinal bleeding: A multisite retrospective study.
Wiedel, Noah A; Sayles, Harlan; Larson, Jessica; Wardian, Jana L; Hewlett, Alexander; McClay, James; Ge, Jin; Anzalone, Alfred Jerrod.
Afiliación
  • Wiedel NA; Department of Internal Medicine, Division of Hospital Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Sayles H; Department of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Larson J; Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Wardian JL; Department of Internal Medicine, Division of Hospital Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Hewlett A; Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • McClay J; Department of Health Management & Informatics, University of Missouri School of Medicine, Columbia, Missouri, USA.
  • Ge J; Department of Medicine, Division of Gastroenterology and Hepatology, University of California at San Francisco, San Francisco, California, USA.
  • Anzalone AJ; Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA.
J Med Virol ; 95(10): e29100, 2023 10.
Article en En | MEDLINE | ID: mdl-37786247
Little data is available regarding the incidence of gastrointestinal bleeding in adults hospitalized with COVID-19 infection and the influence of patient comorbidities and demographics, COVID-19 therapies, and typical medications used. In this retrospective study, we utilized the National COVID Cohort Collaborative to investigate the primary outcome of the development of gastrointestinal bleeding in 512 467 hospitalized US adults (age >18 years) within 14 days of a COVID-19 infection and the influence of demographics, comorbidities, and selected medications. Gastrointestinal bleeding developed in 0.44% of patients hospitalized with COVID-19. Comorbidities associated with gastrointestinal bleeding include peptic ulcer disease (adjusted odds ratio [aOR] 10.2), obesity (aOR 1.27), chronic kidney disease (aOR 1.20), and tobacco use disorder (aOR 1.28). Lower risk of gastrointestinal bleeding was seen among women (aOR 0.76), Latinx (aOR 0.85), and vaccinated patients (aOR 0.74). Dexamethasone alone or with remdesivir was associated with lower risk of gastrointestinal bleeding (aOR 0.69 and aOR 0.83, respectively). Remdesivir monotherapy was associated with upper gastrointestinal bleeding (aOR 1.25). Proton pump inhibitors were more often prescribed in patients with gastrointestinal bleeding, likely representing treatment for gastrointestinal bleeding rather than a risk factor for its development. In adult patients hospitalized with COVID-19, the use of dexamethasone alone or in combination with remdesivir is negatively associated with gastrointestinal bleeding. Remdesivir monotherapy is associated with increased risk of upper gastrointestinal bleeding.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Pacientes Internos Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans Idioma: En Revista: J Med Virol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 / Pacientes Internos Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans Idioma: En Revista: J Med Virol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos